MegaPro Biomedical Co

MegaPro Biomedical Co DSCR

The Debt Service Coverage Ratio (DSCR) of MegaPro Biomedical Co (6827.TWO) as of Oct 15, 2026 is -25.50. In the previous year, Debt Service Coverage Ratio (DSCR) was -11.99 — a change of 112.73% (lower).

DSCR

-25.50

YoY

112.73%

Last updated:

Debt Service Coverage Ratio (DSCR) of MegaPro Biomedical Co is 2024 -25.50 . Debt Service Coverage Ratio (DSCR) of MegaPro Biomedical Co was 2023 -11.99 . It decreases by 112.73% lower compared to the previous year.

The MegaPro Biomedical Co DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2021
-5.31 TWD
Jan 1, 2022
-7.58 TWD
Jan 1, 2023
-11.99 TWD
Jan 1, 2024
-25.50 TWD
The MegaPro Biomedical Co DSCR history
YEARDSCRYoY
-25.50+112.73%
-11.99+58.21%
-7.58+42.72%
-5.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MegaPro Biomedical Co Stock analysis

What does MegaPro Biomedical Co do? MegaPro Biomedical Co Ltd is a biotechnology company based in Zhubei, Taiwan, operating within the health care sector. The company has a workforce of 20 employees and completed its initial public offering (IPO) on October 19, 2021. Its primary focus is the development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's product portfolio includes several compounds designated as MPB-1514, MPB-1523, MPB-1734, and MPB-2043. MPB-1514 is designed for intravenous treatment of anemia associated with chronic kidney disease. MPB-1523 is intended for intravenous diagnosis of hepatocellular carcinoma. MPB-1734 targets solid tumors through intravenous administration. MPB-2043 is used for intravenous diagnosis of metastases in peripheral lymph nodes near cancerous sites. The company maintains a website at https://www.megaprobio.com/ for further information. MegaPro Biomedical Co Ltd operates under the ticker symbol 6827.TWO and is registered with ISIN TW0006827009. It is headquartered in Zhubei, Hsinchu, Taiwan, and is engaged in the development of advanced biotechnological solutions for medical applications. MegaPro Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MegaPro Biomedical Co stock

Debt Service Coverage Ratio (DSCR) of MegaPro Biomedical Co is -25.50 in 2024.

Debt Service Coverage Ratio (DSCR) of MegaPro Biomedical Co changed from -11.99 to -25.50, representing a 112.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) MegaPro Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s MegaPro Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — MegaPro Biomedical Co

All Key Metrics — MegaPro Biomedical Co